UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: February 2015 (Report No. 3)

 

Commission file number: 001-36578

 

BIO BLAST PHARMA LTD.

(Translation of registrant's name into English)

 

37 Dereh Menechem Begin St., 15^th Floor

Tel Aviv 6522042 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x  Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

CONTENTS

 

 

This Report of Foreign Private Issuer on Form 6-K of the registrant consists of the press release issued by the registrant on February 17, 2015, announcing the registrant’s financial results for the fourth quarter ended December 31, 2014, which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

Exhibit No.

 

99.1

Press Release issued by Bio Blast Pharma Ltd. on February 17, 2015, announcing its financial results for the fourth quarter ended December 31, 2014.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Bio Blast Pharma Ltd.
	(Registrant)
	By /s/ Colin Foster
	Name: Colin Foster
	Chief Executive Officer and President

 

Date: February 17, 2015